SANUWAVE Health, Inc. (SNWV): Results of Operations and Financial Condition
SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex-991snwvpressreleasex806.htm EX-99.1 Document Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income w
How this was made
The 30-second read
Why it matters
The company withdrew FY2026 guidance and signaled it will actively comment on CMS’s proposed 2027 97610 reimbursement rule, implying earnings visibility is reduced until the final rule in Q4 2026.
Market read
Traders get a fresh datapoint set: Q2 financials, a shift in guidance policy, and a clear regulatory timeline risk into Q4 2026.
What to watch
The company attributes system sales softness to used-system market emergence and CMS recoupments, so investors should separate demand strength (applicators) from near-term channel mix (systems).
Background
Sanuwave sells Ultramist wound care systems and applicators, and its outlook is tied to Medicare reimbursement for CPT 97610.
Ticker impact
Sanuwave reported Q2 FY2026 results and withdrew prior FY2026 guidance due to Medicare reimbursement uncertainty tied to CMS’s 2027 97610 rule.
Likely downside bias and higher volatility until CMS issues the final 2027 97610 rule in Q4 2026.
The filing discloses revenue decline, operating loss deterioration, and a specific decision to withdraw guidance pending CMS final rule clarity, which directly affects expected cash flows and valuation.
Market effects
Highlights reimbursement sensitivity for advanced wound care and potential read-through volatility for similarly positioned medtech names.
Limited direct regional spillover; primarily US Medicare/HOPD reimbursement-driven.
Low global relevance, as the catalyst is US CMS reimbursement rulemaking.
Counterpoint
Despite system sales weakness, Ultramist applicator unit volumes hit record levels and sequentially increased, suggesting demand may reassert once reimbursement mechanics stabilize.
Key entities
- companySANUWAVE Health, Inc.
NASDAQ-listed wound care product company filing an 8-K with Q2 FY2026 results and guidance withdrawal.
- regulatorCMS
US Centers for Medicare and Medicaid Services proposing reimbursement rule changes affecting CPT 97610.
- billing codeCPT 97610
Reimbursement code referenced as central to the proposed 2027 rule and Sanuwave’s revenue outlook.
